Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT)
Journal of the European Academy of Dermatology and Venereology · 2024
DOI: 10.1111/jdv.19730 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von Fabio Verardi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Psoriasis, Biological Products. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: AbbVie, Almirall, Bristol-Myers Squibb.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Psoriasis is a disease that often requires prolonged systemic treatment. It is important to determine the safety of available therapies. There is currently little insight into sex‐specific differences in the safety of systemic psoriasis therapies.
Objectives
To examine the real‐world, long‐term safety of systemic psoriasis therapies with sex stratification in drug‐related adverse events (ADRs).
Methods
Ten‐year data from adults with moderate‐to‐severe psoriasis requiring systemic treatment (conventional systemic therapies [CST], biologics) were obtained from the Swiss psoriasis registry (SDNTT). ADRs were categorized according to the international terminology Medical Dictionary for Regulatory Activities (MedDRA). Safety was assessed by calculating event rates per 100 patient‐years (PY). We used descriptive statistics for patient and disease characteristics, and binomial and t ‐tests to compare treatment groups and sex.
Results
In total, 791 patients (290 females) were included with a mean age of 46 years. 358 (45%) received CSTs and 433 (55%) biologics; both groups had similar baseline characteristics except for more joint involvement in patients using biologics (26.86% vs. 14.8%, p < 0.0001). CSTs were associated with a 2.2‐fold higher ADR rate (40.43/100 PY vs. 18.22/100 PY, p < 0.0001) and an 8.0‐fold higher drug‐related discontinuation rate than biologics (0.16/PY vs. 0.02/PY, p < 0.0001). Trends showed non‐significant higher serious adverse event rates per 100 PY for biologics (8.19, CI 6.87–9.68) compared to CSTs (7.08, CI 5.39–9.13) ( p = 0.3922). Sex stratification revealed a significantly higher overall ADR rate for all treatments in females (1.8‐fold for CSTs [57.30/100 PY vs. 31.69/100 PY] and 2.0‐fold for biologics [27.36/100 PY vs. 13.9/100 PY], p < 0.0001), and drug‐related discontinuation rates for most CSTs in females.
Conclusion
Females were associated with a significantly higher rate of ADRs and drug‐related discontinuation rates. Sex stratification should be taken into consideration when designing studies in the patient‐tailored management of psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
- Faculty of Medicine, University of Zurich, Zurich, Switzerland.
- Department of Dermatology, University Hospital Basel, Basel, Switzerland.
- Oxford School of Surgery, Oxford Business Park, Oxford, UK.
- Swiss4ward, Statistician and Data Analyst, Zurich, Switzerland.
- Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
ORCID-Profile: Fabio Verardi, Christina Sorbe, Nikhil Yawalkar, Alexander Egeberg, Kristine Heidemeyer, Curdin Conrad, Andreas Pinter, Alexander A Navarini, Julia-Tatjana Maul
Förderung
- AbbVie
- Almirall
- Bristol-Myers Squibb
- Janssen-Cilag
- UCB
Zitieren
APA
Verardi, F., Maul, L. V., Borsky, K., Steinmann, S., Rosset, N., Pons, H. O., Sorbe, C., Yawalkar, N., Micheroli, R., Egeberg, A., Thyssen, J. P., Heidemeyer, K., Boehncke, W. H., Conrad, C., Cozzio, A., Pinter, A., Kündig, T., Navarini, A. A., & Maul, J. T. (2024). Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT). Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19730
Vancouver
Verardi F, Maul LV, Borsky K, Steinmann S, Rosset N, Pons HO, et al. Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT). Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19730
BibTeX
@article{Verardi2024,
author = {Verardi, Fabio and Maul, Lara Valeska and Borsky, Kim and Steinmann, Simona and Rosset, Nina and Pons, Hector Ortega and Sorbe, Christina and Yawalkar, Nikhil and Micheroli, Raphael and Egeberg, Alexander and Thyssen, Jacob P and Heidemeyer, Kristine and Boehncke, Wolf-Henning and Conrad, Curdin and Cozzio, Antonio and Pinter, Andreas and Kündig, Thomas and Navarini, Alexander A and Maul, Julia-Tatjana},
title = {Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT)},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2024},
doi = {10.1111/jdv.19730}
}
EUVIMED